GeneFrontier, formed as an solution provider for genome-based drug research & development, has the strengths of two shareholders:

- Business creation expertise and broad business network of ITX Corporation,
- Biotechnology and extensive clinical laboratory experience of BML, Inc.,

Human Combinatiorial Monoclonal Antibody Service

“Koutai Shokunin” represents Customized Human Monoclonal Antibody Service, using proven MorphoSys AG’s recombinant antibody technology providing high quality monoclonal antibodies in just 10 weeks.The HuCAL GOLD library contains over 15 billion unique human antibody genes in Fab format. This wealth and diversity of sequences is coupled with proprietary automated screening techniques and advanced data management systems to quickly identify the best antibody for your antigen. Monoclonal antibody generation takes place completely in vitro and involves no animals

- More than 15 billion individual antibody specificities available for screening
- Monoclonal antibodies will be delivered in just 10 weeks.
- As little as 0.5mg of protein is needed as antigen
- Optimized antigen expression from DNA
- High-affinity antibody formats show low background
- Antibodies are supplied ready-tagged for further analysis

Clonetics Conditionally Immortalized Cells

“Clonetics Conditionally Immortalized Cells” are ideal cell lines for drug discovery.Immortalized cell lines offer the possibility of an inexhaustible supply of cells that can be used as models of animal or human tissues. However, a major limitation of current technology is that the available models are almost invariably poor representations of cells found in intact tissues. One major reason for this is that the process that allows the cells to become immortal also has an impact on the characteristics of the cell.Cambrex Bioproducts overcomes this limitation using a temperature dependent, conditional immortalization approach utilizing Large T-Antigen that allows the immortalization to be reversed and the cells to revert to their original characteristics. This allows development of cell lines from a wide range of human and animal tissues, and of novel models relevant to drug discovery based on lines from people with particular diseases.